Neurocrine Biosciences, Inc.
NBIXNASDAQHealthcare● Active
$163.12
$-0.76(-0.46%)
Market Cap$16.4B
P/E Ratio—
52W High$169.57
52W Low$122.14
Neurocrine Biosciences, Inc.（NBIX）· 资产负债表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · NBIX · 截至 2026-06-10
财务报表
Total Assets · Total Liabilities · Equity
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Assets | |||||
| Cash & ST Investments | $1.48B | $1.08B | $1.03B | $0.99B | $0.71B |
| Net Receivables | $0.69B | $0.48B | $0.44B | $0.35B | $0.19B |
| Inventory | $0.07B | $0.06B | $0.04B | $0.04B | $0.03B |
| Total Current Assets | $2.52B | $1.72B | $1.61B | $1.45B | $0.97B |
| PP&E Net | $0.55B | $0.59B | $0.35B | $0.15B | $0.16B |
| Goodwill | $0.00B | $0.01B | $0.00B | $0.00B | $0.00B |
| Intangible Assets | $0.00B | $0.04B | $0.04B | $0.04B | $0.00B |
| Total Assets | $4.63B | $3.72B | $3.25B | $2.37B | $2.07B |
| Liabilities | |||||
| Short-Term Debt | $0.00B | $0.00B | $0.17B | $0.17B | $0.00B |
| Accounts Payable | $0.10B | $0.11B | $0.13B | $0.07B | $0.05B |
| Total Current Liabilities | $0.74B | $0.51B | $0.65B | $0.54B | $0.25B |
| Long-Term Debt | $0.00B | $0.00B | $0.00B | $0.00B | $0.34B |
| Total Liabilities | $1.38B | $1.13B | $1.02B | $0.66B | $0.70B |
| Stockholders Equity | |||||
| Retained Earnings | $0.45B | $0.03B | ($0.16B) | ($0.41B) | ($0.64B) |
| Total Stockholders Equity | $3.25B | $2.59B | $2.23B | $1.71B | $1.37B |
| Total Liab & Equity(computed) | $4.63B | $3.72B | $3.25B | $2.37B | $2.07B |
| Debt Summary | |||||
| Total Debt | $0.42B | $0.46B | $0.43B | $0.26B | $0.44B |
| Net Debt | ($0.30B) | $0.22B | $0.18B | $0.00B | $0.10B |
数据来源：Financial Modeling Prep · 最后更新：2026-06-10 · USD · B
深入了解Neurocrine Biosciences, Inc.
关于Neurocrine Biosciences, Inc.（NBIX）资产负债表
Neurocrine Biosciences, Inc.总资产$4.63B，现金及短期投资$1.48B，总负债$1.38B，总债务$0.42B，股东权益$3.25B。
常见问题
NBIX · 4 问Neurocrine Biosciences, Inc.总债务$0.42B，净债务($0.30B)。
NBIX total debtnet debtdebt to equity
· Source: FMP /stable/balance-sheet-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10